Pfizer Korea (CEO Dong-wook Oh) ​​announced on the 22nd that Benefix (Recombinant Blood Coagulation Factor Ⅸ), a hemophilia B treatment, was additionally approved by the MFDS for an indication for routine preventive therapy administered once a week.

For those over 12 years of age who are injecting Benefix, a dose of 100 IU/kg once a week is recommended to prevent long-term bleeding, and the dosage should be adjusted according to the patient's clinical response.

Benefix is ​​the first factor IX genetically modified hemophilia treatment that has been used for over 20 years for supplemental and prophylactic treatment of pediatric and adult hemophilia patients. Benef